menu
    • menu

    Company profile for Amal Therapeutics SA

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    AMAL Therapeutics (AMAL) is a pre-clinical stage Swiss biotech, developing unique therapeutic vaccines. Our aim is to overcome the challenges around effective anti-cancer therapy by stimulating a patient’s immune system in a unique way, in order to create immunological memory, as well as target a broad range of patients. Our headquarters and laboratory facilities are located on the campus of the University of Geneva providi...
    AMAL Therapeutics (AMAL) is a pre-clinical stage Swiss biotech, developing unique therapeutic vaccines. Our aim is to overcome the challenges around effective anti-cancer therapy by stimulating a patient’s immune system in a unique way, in order to create immunological memory, as well as target a broad range of patients. Our headquarters and laboratory facilities are located on the campus of the University of Geneva providing access to state of the art platforms and know-how. ATP128, our lead program in metastatic colorectal cancer is expected to enter the clinic in 2019.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Amal Therapeutics SASwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    c/o Fondation pour Recherches Médicales, 64 av. de la Roseraie, 1205 Geneva
    Telephone
    Telephone
    +41 (0) 22 379 46 88
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.amaltherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/amal-therapeutics
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    After inking a string of pipeline deals, Boehringer Ingelheim is doing makeover
    After inking a string of pipeline deals, Boehringer Ingelheim is doing makeover

    26 Aug 2019

    // John Carroll ENDPTS

    https://endpts.com/after-inking-a-string-of-pipeline-deals-boehringer-ingelheim-is-doing-a-makeover-of-the-top-executive-team/

    John Carroll ENDPTS
    26 Aug 2019
    Share Share
    Boehringer enriches cancer immunology portfolio by AMAL Therapeutics acquisition
    Boehringer enriches cancer immunology portfolio by AMAL Therapeutics acquisition

    18 Jul 2019

    // Anna Smith PHARMATIMES

    http://www.pharmatimes.com/news/boehringer_enriches_cancer_immunology_portfolio_with_amal_therapeutics_acquisition_1294698

    Anna Smith PHARMATIMES
    18 Jul 2019
    Share Share
    Boehringer buys up cancer vaccine player, eyes oncology combo strategy
    Boehringer buys up cancer vaccine player, eyes oncology combo strategy

    16 Jul 2019

    // Ben Adams FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/boehringer-buys-up-cancer-vaccine-player-eyeing-oncology-combo-strategy?utm_source=internal&utm_medium=rss

    Ben Adams FIERCE BIOTECH
    16 Jul 2019
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search